MEI PHARMA INC (MEIP)
US55279B3015 - Common Stock
We assign a fundamental rating of 5 out of 10 to MEIP. MEIP was compared to 588 industry peers in the Biotechnology industry. MEIP has an excellent financial health rating, but there are some minor concerns on its profitability. MEIP has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year MEIP was profitable.
MEIP had a negative operating cash flow in the past year.
In the past 5 years MEIP always reported negative net income.
MEIP had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
MEIP's Return On Assets of 25.26% is amongst the best of the industry. MEIP outperforms 99.66% of its industry peers.
MEIP has a Return On Equity of 33.35%. This is amongst the best in the industry. MEIP outperforms 98.63% of its industry peers.
Looking at the Return On Invested Capital, with a value of 17.79%, MEIP belongs to the top of the industry, outperforming 98.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.26% | ||
| ROE | 33.35% | ||
| ROIC | 17.79% |
ROA(3y)-26.9%
ROA(5y)-24.71%
ROE(3y)-105.6%
ROE(5y)-82.62%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 27.30%, MEIP belongs to the top of the industry, outperforming 98.80% of the companies in the same industry.
The Operating Margin of MEIP (21.86%) is better than 97.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.86% | ||
| PM (TTM) | 27.3% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MEIP has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for MEIP remains at a similar level compared to 1 year ago.
Compared to 5 years ago, MEIP has more shares outstanding
MEIP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -3.30, we must say that MEIP is in the distress zone and has some risk of bankruptcy.
MEIP's Altman-Z score of -3.30 is in line compared to the rest of the industry. MEIP outperforms 43.66% of its industry peers.
There is no outstanding debt for MEIP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.3 |
ROIC/WACC1.91
WACC9.34%
2.3 Liquidity
MEIP has a Current Ratio of 8.23. This indicates that MEIP is financially healthy and has no problem in meeting its short term obligations.
MEIP has a Current ratio of 8.23. This is in the better half of the industry: MEIP outperforms 74.49% of its industry peers.
MEIP has a Quick Ratio of 8.23. This indicates that MEIP is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 8.23, MEIP is doing good in the industry, outperforming 74.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.23 | ||
| Quick Ratio | 8.23 |
3. Growth
3.1 Past
MEIP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 164.57%, which is quite impressive.
Looking at the last year, MEIP shows a quite strong growth in Revenue. The Revenue has grown by 16.11% in the last year.
Measured over the past years, MEIP shows a very strong growth in Revenue. The Revenue has been growing by 97.61% on average per year.
EPS 1Y (TTM)164.57%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-203.75%
Revenue 1Y (TTM)16.11%
Revenue growth 3Y20.71%
Revenue growth 5Y97.61%
Revenue growth Q2Q-100%
3.2 Future
Based on estimates for the next years, MEIP will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.41% on average per year.
MEIP is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -12.34% yearly.
EPS Next Y172.37%
EPS Next 2Y-13.52%
EPS Next 3Y6.79%
EPS Next 5Y12.41%
Revenue Next Year35.4%
Revenue Next 2Y-64.02%
Revenue Next 3Y-19.7%
Revenue Next 5Y-12.34%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 1.03, which indicates a rather cheap valuation of MEIP.
99.32% of the companies in the same industry are more expensive than MEIP, based on the Price/Earnings ratio.
MEIP is valuated cheaply when we compare the Price/Earnings ratio to 24.92, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for MEIP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.03 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -5.73 |
4.3 Compensation for Growth
MEIP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y-13.52%
EPS Next 3Y6.79%
5. Dividend
5.1 Amount
MEIP has a Yearly Dividend Yield of 57.38%, which is a nice return.
The stock price of MEIP dropped by -32.97% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
Compared to an average industry Dividend Yield of 24.34, MEIP pays a better dividend. On top of this MEIP pays more dividend than 99.83% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.41, MEIP pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 57.38% |
5.2 History
MEIP does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y-13.52%
EPS Next 3Y6.79%
MEI PHARMA INC
NASDAQ:MEIP (4/26/2024, 7:03:08 PM)
3.05
-0.05 (-1.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap20.31M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 57.38% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.03 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.01
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.26% | ||
| ROE | 33.35% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 21.86% | ||
| PM (TTM) | 27.3% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.93
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8.23 | ||
| Quick Ratio | 8.23 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)164.57%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y172.37%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)16.11%
Revenue growth 3Y20.71%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y